Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 2Neoplasm, Residual 1Myelodysplastic Syndromes 1Melanoma 1Leukemia, Myelomonocytic, Chronic 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 235Pemetrexed 214Paclitaxel 160Cisplatin 150pembrolizumab 145Erlotinib Hydrochloride 141Docetaxel 133Gemcitabine 94Bevacizumab 85Nivolumab 72Radiotherapy 62atezolizumab 40Radiosurgery 37Afatinib 37osimertinib 35130-nm albumin-bound paclitaxel 35Cetuximab 34durvalumab 33Ipilimumab 32Gefitinib 31Albumin-Bound Paclitaxel 29Vinorelbine 23Taxes 22Etoposide 20Crizotinib 19Radiation 17Sorafenib 16Cyclophosphamide 16Dexamethasone 15Magnetic Resonance Spectroscopy 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Non-Small-Cell Lung × sabatolimab × Clear all
NCT02608268 2023-12-06

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Novartis

Phase 1/2 Terminated
252 enrolled 67 charts
DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡